Sofinnova Ventures Company Profile

04:49 EDT 21st September 2018 | BioPortfolio

Sofinnova Ventures we are company builders who work with our entrepreneurs as a team. Our firm, based in San Francisco and founded in 1974, invests venture capital in early-stage Life Science and Information Technology startup companies. Our mission is to provide entrepreneurs with the resources, experience and skill sets necessary to grow early-stage companies into great businesses.Sofinnova Ventures combines extensive venture-capital experience with deep technical, startup and operational management. We are experienced entrepreneurs, having founded, operated, acquired, sold, and taken public companies in our operational careers. We run Sofinnova Ventures itself in an aggressive, smart, entrepreneurial fashion.While our primary value to entrepreneurs is our experience and the active, company-building help we offer, we also offer trans-Atlantic synergy and market acceleration to our entrepreneurs. Because of our strong ties to Europe's leading financial, technology and venture companies, we help U.S. companies quickly enter Europe's booming markets, and our European companies to develop a strong presence in the strategic U.S. high-tech markets.


140 Geary Street Tenth floor
San Francisco
United States of America


Phone: 415 228 3380
Fax: 415 228 3390

News Articles [399 Associated News Articles listed on BioPortfolio]

Neurana brings in $60mm Series A round

CNS-focused Neurana Pharmaceuticals Inc. (formerly Katama) closed a $60mm Series A round led by Sofinnova Ventures. New Leaf Venture Partners, HIG BioHealth Partners, Longitude Capital, and MagnaSci V...

Sofinnova crosses over

Sofinnova Partners raised its first crossover fund to attract international investors to late-stage EU biotechs.

Akouos Raises $50M to Advance Precision Medicine for Hearing Disorders

Akouos, a Boston, MA-based precision genetic medicine company developing gene therapies that restore and preserve hearing has raised $50 million in Series A funding co-led by 5AM Ventures and New Ent...

$340M life sciences crossover fund launched by Sofinnova Partners

The life sciences-focused Sofinnova Crossover Fund I was launched by Paris-based venture capital firm Sofinnova Partners afte -More- 

Antoine Papiernik, Managing Partner: How Sofinnova Partners achieve high returns through taking calculated risks.

Sofinnova invest early in projects with disruptive technologies that have the potential to become strong sustainable companies with the potential to return in excess of 10x their investment. Antoine P...

French Crossover Fund Raises €275M to Invest in Medical Biotechs

Sofinnova Partners has launched a crossover fund focusing on European companies to support medical biotechs across all funding stages, from seed to late stage.  Sofinnova Partners, the largest French...

Sofinnova Targets Later Stage Firms With €275M Healthcare Crossover Fund

After four decades of exclusively backing early stage life science start-ups, French venture capitalist Sofinnova Partners has launched its first...   

League raises fresh capital to grow employee health benefits platform

The Canadian startup secured C$62 million (or about $47.5 million) in a round led by TELUS Ventures. Wittington Ventures, OMERS, RBC Ventures, Real Ventures, Infinite Potential Group and BDC IT Ventu...

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Avant ex [B4 Ventures LLC]

B4 Brands: Avant EX Instant Hand Sanitizer

Avant foaming hand sanitizer [B4 Ventures LLC]

B4 Brands: Avant Foaming Hand Sanitizer - Fragrance Free

Avant original instant hand sanitizer [B4 Ventures LLC]

B4 Brands: Avant Original Instant Hand Sanitizer

Aterra antibacterial hand wash [B4 Ventures LLC]

B4 Brands: Aterra Antibacterial Hand Soap

Avant original - fragrance free [B4 Ventures LLC]

B4 Brands: Avant Original - Fragrance Free Instant Hand Sanitizer

PubMed Articles [5 Associated PubMed Articles listed on BioPortfolio]

Outsourcing of Academic Clinical Laboratories: Experiences and Lessons From the Association of Pathology Chairs Laboratory Outsourcing Survey.

American hospitals are increasingly turning to service outsourcing to reduce costs, including laboratory services. Studies of this practice have largely focused on nonacademic medical centers. In cont...

Estimating and valuing the carbon release in scenarios of land-use and climate changes in a Brazilian coastal area.

Deforestation is a significant source of man-made carbon in the atmosphere, contributing to the greenhouse gas (GHG) effect. Although carbon releases are associated to the ecosystem functions of clima...

"Yes, we know!" (Over)confidence in general knowledge among Austrian entrepreneurs.

Overconfidence has been reported to be a common bias among entrepreneurs and might be one cause of the high failure rates observed for new ventures. In this study, we investigate the overconfidence bi...

The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses.

It is evidenced that 20% of all tumors in humans are caused by oncoviruses including Human Papilloma Viruses (HPV), Epstein-Barr Virus (EBV), Kaposi Sarcoma Virus (KSHV), Human Polyomaviruses (HPyV), ...

Detecting opinion spams through supervised boosting approach.

Product reviews are the individual's opinions, judgement or belief about a certain product or service provided by certain companies. Such reviews serve as guides for these companies to plan and monito...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Evaluation of a Digital Microscope for Malaria

Light microscopy, which is based on century-old technology, remains a key indicator in drug efficacy testing performed in the context of clinical trials for monitoring existing antimalaria...

Field Evaluation of a Device for Automated Malaria Microscopy (Autoscope Version 2)

Microscopy remains a key indicator in drug efficacy testing performed in the context of clinical trials for monitoring existing antimalarials or in the context of regulatory clinical trial...

Companies [558 Associated Companies listed on BioPortfolio]

Sofinnova Ventures

Sofinnova Ventures we are company builders who work with our entrepreneurs as a team. Our firm, based in San Francisco and founded in 1974, invests venture capital in early-stage Life Science and Info...

Sofinnova Partners

1972 Sofinnova is the first venture capital company created in France.Sofinnova Partners is an independent venture capital company based in Paris. We have special relations with Sofinnova Ventures, o...


NuCana® is a rapidly growing, clinical stage biopharmaceutical company with a broad development portfolio of novel anti-cancer medicines. The Company’s proprietary ProTide...

Marinus Pharmaceuticals, Inc.

Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders. Marinus ...

Catalyst Biosciences, Inc.

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery p...

More Information about "Sofinnova Ventures" on BioPortfolio

We have published hundreds of Sofinnova Ventures news stories on BioPortfolio along with dozens of Sofinnova Ventures Clinical Trials and PubMed Articles about Sofinnova Ventures for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sofinnova Ventures Companies in our database. You can also find out about relevant Sofinnova Ventures Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record